We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Stock Moves -0.89%: What You Should Know
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) ended the recent trading session at $55.78, demonstrating a -0.89% swing from the preceding day's closing price. On the other hand, the Dow registered a loss of 0.2%, and the technology-centric Nasdaq increased by 0.12%.
Prior to today's trading, shares of the biopharmaceutical company had lost 3.79% over the past month. This has was narrower than the Medical sector's loss of 4.31% and lagged the S&P 500's gain of 1.27% in that time.
Investors will be eagerly watching for the performance of Bristol Myers Squibb in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 6, 2025. The company is expected to report EPS of $1.47, down 13.53% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $11.6 billion, indicating a 1.05% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.91 per share and a revenue of $47.56 billion, representing changes of -87.88% and +5.67%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.99% higher. Bristol Myers Squibb currently has a Zacks Rank of #2 (Buy).
In terms of valuation, Bristol Myers Squibb is presently being traded at a Forward P/E ratio of 61.83. For comparison, its industry has an average Forward P/E of 23.1, which means Bristol Myers Squibb is trading at a premium to the group.
We can additionally observe that BMY currently boasts a PEG ratio of 15.46. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.83.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 67, finds itself in the top 27% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Stock Moves -0.89%: What You Should Know
Bristol Myers Squibb (BMY - Free Report) ended the recent trading session at $55.78, demonstrating a -0.89% swing from the preceding day's closing price. On the other hand, the Dow registered a loss of 0.2%, and the technology-centric Nasdaq increased by 0.12%.
Prior to today's trading, shares of the biopharmaceutical company had lost 3.79% over the past month. This has was narrower than the Medical sector's loss of 4.31% and lagged the S&P 500's gain of 1.27% in that time.
Investors will be eagerly watching for the performance of Bristol Myers Squibb in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 6, 2025. The company is expected to report EPS of $1.47, down 13.53% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $11.6 billion, indicating a 1.05% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.91 per share and a revenue of $47.56 billion, representing changes of -87.88% and +5.67%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.99% higher. Bristol Myers Squibb currently has a Zacks Rank of #2 (Buy).
In terms of valuation, Bristol Myers Squibb is presently being traded at a Forward P/E ratio of 61.83. For comparison, its industry has an average Forward P/E of 23.1, which means Bristol Myers Squibb is trading at a premium to the group.
We can additionally observe that BMY currently boasts a PEG ratio of 15.46. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.83.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 67, finds itself in the top 27% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.